Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Elife. 2024 May 8;12:RP89999. doi: 10.7554/eLife.89999.
SARS-CoV-2 vaccines have been used worldwide to combat COVID-19 pandemic. To elucidate the factors that determine the longevity of spike (S)-specific antibodies, we traced the characteristics of S-specific T cell clonotypes together with their epitopes and anti-S antibody titers before and after BNT162b2 vaccination over time. T cell receptor (TCR) αβ sequences and mRNA expression of the S-responded T cells were investigated using single-cell TCR- and RNA-sequencing. Highly expanded 199 TCR clonotypes upon stimulation with S peptide pools were reconstituted into a reporter T cell line for the determination of epitopes and restricting HLAs. Among them, we could determine 78 S epitopes, most of which were conserved in variants of concern (VOCs). After the 2nd vaccination, T cell clonotypes highly responsive to recall S stimulation were polarized to follicular helper T (Tfh)-like cells in donors exhibiting sustained anti-S antibody titers (designated as 'sustainers'), but not in 'decliners'. Even before vaccination, S-reactive CD4 T cell clonotypes did exist, most of which cross-reacted with environmental or symbiotic microbes. However, these clonotypes contracted after vaccination. Conversely, S-reactive clonotypes dominated after vaccination were undetectable in pre-vaccinated T cell pool, suggesting that highly responding S-reactive T cells were established by vaccination from rare clonotypes. These results suggest that de novo acquisition of memory Tfh-like cells upon vaccination may contribute to the longevity of anti-S antibody titers.
SARS-CoV-2 疫苗已在全球范围内用于对抗 COVID-19 大流行。为了阐明决定刺突(S)特异性抗体寿命的因素,我们跟踪了 BNT162b2 接种前后 S 特异性 T 细胞克隆型及其表位和抗 S 抗体滴度的特征。使用单细胞 TCR 和 RNA 测序研究了 T 细胞受体(TCR)αβ序列和 S 应答 T 细胞的 mRNA 表达。使用 S 肽池刺激后,高度扩增的 199 个 TCR 克隆型被重建为报告 T 细胞系,以确定表位和限制 HLA。其中,我们可以确定 78 个 S 表位,其中大多数在关注变体(VOC)中保守。在第二次接种后,在表现出持续抗 S 抗体滴度的供体(指定为“维持者”)中,对召回 S 刺激高度反应的 T 细胞克隆型被极化到滤泡辅助 T(Tfh)样细胞,但在“下降者”中没有。即使在接种疫苗之前,也存在对 S 有反应的 CD4 T 细胞克隆型,其中大多数与环境或共生微生物发生交叉反应。然而,这些克隆型在接种疫苗后收缩。相反,接种疫苗后占主导地位的 S 反应性克隆型在接种前的 T 细胞库中无法检测到,这表明高反应性的 S 反应性 T 细胞是通过从稀有克隆型接种疫苗而建立的。这些结果表明,接种疫苗后记忆性 Tfh 样细胞的从头获得可能有助于抗 S 抗体滴度的持久性。